Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$25.11 +2.9%	$23.76	$20.92 ▼ $42.48	$46.24B	N/A	219,911 shs	141,859 shs
ONC BeOne Medicines	$321.36 +3.8%	$274.62	$170.99 ▼ $321.69	$33.94B	0.27	436,213 shs	448,792 shs
ORINY Orion OYJ	$38.43	$38.38	$21.95 ▼ $41.60	$10.85B	0.1	553 shs	32 shs
TAK Takeda Pharmaceutical	$14.99 +1.3%	$14.79	$12.80 ▼ $15.53	$47.09B	0.22	5.57 million shs	2.30 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	+2.87%	+2.91%	+7.58%	+3.42%	-35.94%
ONC BeOne Medicines	+3.77%	+11.51%	+15.12%	+40.71%	+32,135,999,900.00%
ORINY Orion OYJ	0.00%	+0.84%	-1.14%	+23.30%	+67.82%
TAK Takeda Pharmaceutical	+1.26%	+3.67%	+1.87%	+6.27%	+4.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	0.7941 of 5 stars	1.5	0.0	0.0	0.0	2.6	1.7	0.6
ORINY Orion OYJ	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	1.079 of 5 stars	0.0	3.0	2.5	0.0	2.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$330.89	2.97% Upside
ORINY Orion OYJ	2.00	Hold	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORINY, DSNKY, TAK, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$350.00 ➝ $365.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.84	$1.29 per share	19.45	$5.61 per share	4.48
ONC BeOne Medicines	$3.81B	9.24	N/A	N/A	$34.40 per share	9.34
ORINY Orion OYJ	$1.67B	6.50	$1.62 per share	23.71	$3.70 per share	10.39
TAK Takeda Pharmaceutical	$30.09B	1.59	$3.22 per share	4.65	$14.89 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	24.38	23.04	1.20	15.65%	17.92%	8.61%	10/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	452.62	N/A	-3.89%	-1.22%	-0.72%	N/A
ORINY Orion OYJ	$356.98M	$1.47	26.14	29.56	N/A	22.61%	38.68%	22.98%	11/4/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	49.97	9.08	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest ORINY, DSNKY, TAK, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion
7/18/2025	Q2 2025	ORINY Orion OYJ	N/A	$0.33	N/A	$0.33	N/A	$472.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.29	1.15%	N/A	28.16%	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
ORINY Orion OYJ	$0.32	0.83%	N/A	21.77%	N/A
TAK Takeda Pharmaceutical	$0.55	3.67%	N/A	183.33%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
ONC BeOne Medicines	0.04	1.95	1.72
ORINY Orion OYJ	0.15	1.86	1.05
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
ONC BeOne Medicines	48.55%
ORINY Orion OYJ	N/A
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
ONC BeOne Medicines	6.62%
ORINY Orion OYJ	N/A
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
ORINY Orion OYJ	3,712	282.27 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

ORINY, DSNKY, TAK, and ONC Headlines

Recent News About These Companies

US Bancorp DE Trims Position in Takeda Pharmaceutical Co. (NYSE:TAK)

August 10, 2025 | marketbeat.com

XY Capital Ltd Has $1.43 Million Position in Takeda Pharmaceutical Co. (NYSE:TAK)

August 9, 2025 | marketbeat.com

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

August 8, 2025 | newsfilecorp.comN

335,855 Shares in Takeda Pharmaceutical Co. (NYSE:TAK) Bought by ABC Arbitrage SA

August 6, 2025 | marketbeat.com

Natixis Advisors LLC Sells 58,301 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

August 6, 2025 | marketbeat.com

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

August 5, 2025 | afp.comA

Currax cranks up Contrave campaigns, taking obesity ad national and telling patients’ stories

August 5, 2025 | fiercepharma.comF

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by Federated Hermes Inc.

August 3, 2025 | marketbeat.com

Avantax Advisory Services Inc. Has $1.70 Million Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

August 1, 2025 | marketbeat.com

Takeda Pharmaceutical (NYSE:TAK) Sees Large Volume Increase - Should You Buy?

July 31, 2025 | marketbeat.com

Takeda Pharmaceutical (NYSE:TAK) Updates FY 2025 Earnings Guidance

July 31, 2025 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Incyte (INCY)

July 30, 2025 | theglobeandmail.com

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

July 30, 2025 | benzinga.com

Teva execs shrug off pharmaceutical tariff threat as turnaround strategy rolls forward

July 30, 2025 | fiercepharma.comF

Takeda revenue reduced by Vyvanse competition

July 30, 2025 | thepharmaletter.comT

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

July 30, 2025 | seekingalpha.com

Takeda Pharmaceutical 1Q Net Y124.24B Vs Net Y95.25B

July 30, 2025 | marketwatch.com

Takeda Pharmaceutical 1Q Net Profit Beat Y94.89B Expected in Poll of Analysts by Quick>4502.TO

July 30, 2025 | marketwatch.com

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Bank of New York Mellon Corp

July 30, 2025 | marketbeat.com

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

July 30, 2025 | businesswire.com

Pregnancy Incidence Among Isotretinoin Users May Be Affected by Race, Insurance Type

July 24, 2025 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORINY, DSNKY, TAK, and ONC Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$25.11 +0.70 (+2.87%)

As of 08/15/2025 04:00 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

BeOne Medicines NASDAQ:ONC

$321.36 +11.67 (+3.77%)

As of 08/15/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Orion OYJ OTCMKTS:ORINY

$38.43 0.00 (0.00%)

As of 08/14/2025

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Takeda Pharmaceutical NYSE:TAK

$14.99 +0.19 (+1.28%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$14.76 -0.23 (-1.57%)

As of 08/15/2025 06:26 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time